Sponsored Post:
At first, it might be difficult to imagine illicit psychedelic drugs such as “magic mushrooms” being used in clinical settings. But following recent research, this might well be where the future of psychiatry and psychotherapy lies. Spanning the last two decades, this new wave of research is paving the way for the integration of psychedelic-assisted psychotherapy into the Canadian healthcare system. This could involve psychedelic-assisted therapy as a treatment for mental illnesses such as post-traumatic stress disorder (PTSD), anxiety, depression, and addiction. The research on psilocybin has been drawing attention around the world. Disbelief is common when learning that a one-time dose of psilocybin the active component of “magic mushrooms” could produce a sustained remission of depression that lasts from months to years.
Though many of the results are still preliminary and some of the studies involve small sample sizes, the studies consistently demonstrate the remarkable potential of psilocybin-assisted psychotherapy. The research has garnered favorable attention from the U.S. Food and Drug Administration (FDA), which has given the go-ahead for much larger-scale studies on how psilocybin could be used to treat TRD and major depressive disorder. Furthermore, these other sectors are multidisciplinary integrative wellness industries addressing a large, underserved addiction services market. Nearly $8.5 trillion has been lost in economic output due to mental health, substance use, and chronic pain disorders. These sectors also receive about 7% of Canada’s health care dollars. (1) Are you interested to reach a different level of the global psychedelic market? You could take a glance into these prominent industries that are thriving to harness psychedelics’ utmost potential! Is this something that tickles your curiosity? Well, this is a great place to enrich your perspectives!
Considering the magnitude of the burden of mental illness, its developing global prevalence, and flourishing costs of healthcare purely reactive interventions are unlikely to have sufficient impact. Moreover, there is a dearth of truly novel and effective new psychiatric drugs. A vast number of current drugs have a lag in their therapeutic onset, possess a range of side effects, and show modest efficacy relative to placebo, with almost 20% of patients resistant to any of the currently licensed treatment options. Moreover, pure pharmacotherapy, while convenient for “industrial” healthcare, might not have the correct action to target etiological causes in a manner that could serve long-term well-being.
In line with this, these additional realms have an accretive M&A strategy focused on cash-flowing assets. They have acquired nearly 5 mental health and addiction clinics, about 3 specialized pharmacies, and a proprietary addiction-focused platform. Furthermore, significantly undervalued, with a tight float and solid management team, these sectors could follow in the footsteps of many competitors that have seen their commodities strive since going public. They could also be the very first public sectors in the space to enter the market with significant revenue and cash flow. (2) Maintaining your mental health is vital to living a happy and healthy life. But unfortunately, almost millions of people struggle with mental illnesses that leave them feeling hopeless, helpless, and alone. Beat anxiety with psychedelic therapy and dwell on this site now!
Psychedelic medications, when judiciously used in well-regulated settings, serve as a beacon of hope to suffering Canadians and patients across the globe. Given these far-reaching implications, healthcare professionals better stay informed of the rapidly advancing research and clinical developments. Understanding these advances could possibly help nurses to adapt and inform their patients accordingly. You deserve to have a wave of inner peace! Read on, and seize the moment to know more about these mind-boggling medical advances!
Check the disclaimer on my profile and landing page.
Source 2: https://www.frontiersin.org/articles/10.3389/fpsyt.2021.661233/full
